Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Acta Oncologica 2017-Oct

Improved treatment decisions in patients with esophageal cancer.

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Le lien est enregistré dans le presse-papiers
Cecilie Delphin Amdal
Anne-Birgitte Jacobsen
Ragnhild Sørum Falk
Egil Johnson
Silje Skjelsvik Os
Trond Warloe
Kristin Bjordal

Mots clés

Abstrait

BACKGROUND

Patients with esophageal cancer seldom achieve long-term survival. This prospective cohort study investigated the selection of patients likely to benefit from curative treatment and whether information on patients' health-related quality of life (HRQL) would assist treatment decisions in the multidisciplinary team.

METHODS

Consecutive patients completed HRQL assessments and clinical data were collected before start of treatment. Logistic regression analyses identified clinical factors associated with treatment intent in patients with stage-III disease. Kaplan-Meier method was used for survival analyses and Cox proportional hazards models were used to assess the impact of clinical factors and HRQL on survival in patients planned for curative treatment.

RESULTS

Patients with curative treatment intent (n = 90) were younger, had better WHO performance status and less fatigue than patients with palliative treatment intent (n = 89). Median survival for the total cohort (n = 179) and patients with palliative or curative treatment intent was nine, five and 19 months, respectively. In multivariate Cox regression analyses, performance status (0-1 favorable) and comorbidity (ASA I favorable) were factors of importance for survival, whereas measures of HRQL were not.

CONCLUSIONS

Patients performance status and comorbidity must be considered in addition to stage of disease to avoid extensive curative treatment in patients with short life expectancy. This study did not provide evidence to support that information on patients HRQL adds value to the multidisciplinary team's treatment decision process.

Rejoignez notre
page facebook

La base de données d'herbes médicinales la plus complète soutenue par la science

  • Fonctionne en 55 langues
  • Cures à base de plantes soutenues par la science
  • Reconnaissance des herbes par image
  • Carte GPS interactive - étiquetez les herbes sur place (à venir)
  • Lisez les publications scientifiques liées à votre recherche
  • Rechercher les herbes médicinales par leurs effets
  • Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets

Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées

Google Play badgeApp Store badge